



Limited Review Report on unaudited standalone financial results of Sotac Pharmaceutical Limited for the Quarter & Nine Months ended 31st December, 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors Of,
Sotac Pharmaceutical Limited
(Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Sotac Pharmaceutical Limited** ("the Company") for the Quarter & Nine Months ended on December 31, 2023. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.
Chartered Accountants
F.R. No. 141173W



Keyur Shah
Proprietor
M. No. 153774

UDIN: - 24153774BKBNSZ3544

Date: - 05th February, 2024

Place: - Ahmedabad

SOTAC PHARMACEUTICALS LIMITED

(Formerly Known as SOTAC PHARMACEUTICALS PRIVATE LIMITED)

CIN : U24230GJ2015PLC085451

PLOT NO. PF-21, NR. ACME PHARMA, OPP. TEVA PHARMA SANAND, GIDC-II SANAND, AHMEDABAD- 382110

Standalone Financial Results For The Quarter & Nine Months Ended 31st December 2023

Sr. No.	Particulars	Rs. in Lakhs (unless otherwise stated)					
		Quarter Ended			Period Ended		Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income From Operations						
	a) Revenue from Operations	1,768.11	1,420.20	1,405.73	5,079.36	4,480.46	5,798.28
	b) Other Income	27.09	28.81	0.47	79.05	11.78	24.31
	Total Income	1,795.20	1,449.01	1,406.20	5,158.41	4,492.24	5,822.59
II	Expenses						
	a) Cost of Materials Consumed	1,126.61	806.75	1,072.68	3,132.71	3,181.83	4,272.34
	b) Purchase of Stock-In-Trade	80.22	84.53	16.27	172.48	34.49	52.64
	c) Changes in Inventories of Finished Goods Work-In-Progress and Stock-In-Trade	23.05	2.10	10.27	91.51	(18.29)	(318.38)
	d) Employee Benefit Expense	60.56	71.27	72.92	204.10	219.18	292.67
	e) Finance Costs	22.91	19.30	13.28	76.41	55.58	86.13
	f) Depreciation and Amortisation Expense	68.34	63.47	43.18	178.08	117.07	162.53
	g) Other Expenses	184.36	186.59	123.85	690.33	480.59	678.21
	Total Expenses	1,566.05	1,234.01	1,352.45	4,545.62	4,070.45	5,226.14
III	Profit/ (Loss) Before Tax (I-II)	229.15	215.00	53.75	612.79	421.79	596.45
IV	Prior Period Items	(23.20)	-	-	(23.20)	-	-
V	Profit before extraordinary items and tax (III - IV)	205.95	215.00	53.75	589.59	421.79	596.45
VI	Tax Expense						
	a) Current Tax	60.26	51.63	6.41	157.52	119.52	168.39
	b) Deferred Tax (Asset)/Liabilities	0.15	(3.60)	(3.68)	(0.97)	(23.90)	(21.49)
	c) Income Tax Prior Period	(3.79)			(3.79)		
	Total Tax Expense	56.61	48.03	2.73	152.75	95.62	146.90
VII	Net Profit/ (Loss) After Tax for the Period (V-VI)	149.34	166.97	51.02	436.84	326.17	449.55
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	1,105.00	1,105.00	805.00	1,105.00	805.00	805.00
	Reserve & Surplus (Excluding Revaluation Reserve)						346.98
IX	Earnings Per Share (not annualised for quarter ended)						
	Basic / Diluted	2.65	1.52	0.21	5.29	4.05	5.58

Notes to Accounts -Standalone Financial Statement

- [1] The above standalone financial results for the quarter ended December 31, 2023 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 5th February, 2024. A limited review of the above results has been carried out by the statutory auditors of the company.
- [2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified wherever considered necessary.
- [3] The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
- [4] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [5] The Status of investor's complaints during the year ended on December 31, 2023 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel
 Sharad Patel
 DIN: 07252252
 Chairman & Managing director

Place: Sanand
 Date: 05-02-2024